HIV peptides from Tat, Rev and Nef conserved regions and their application as E.G. vaccine components

HIV peptides from Tat, Rev and Nef conserved regions and their application as E.G. vaccine components

  • CN 1,458,936 A
  • Filed: 09/03/2001
  • Published: 11/26/2003
  • Est. Priority Date: 09/04/2000
  • Status: Abandoned Application
First Claim
Patent Images

1. be characterised in that and comprise at least a peptide that is selected from the aminoacid sequence of following aminoacid sequence:

  • Xaa 1?Xaa 2?Xaa 3?Xaa 4?Xaa 5?Xaa 6?Xaa 7?Leu?Glu?Pro?Trp?Xaa 12?His?Pro?Xaa 15?Xaa 16?Xaa 17?Xaa 18?Xaa 19?Xaa 20?Xaa 21?Xaa 22?Xaa 23?Xaa 24(SEQ?ID?NO:

    1) Amino acid in its medium chain can have following implication;

    The Xaa that peptide derivant is 1 is Met, Ser, Cys or do not have,2 Xaa is Glu, Asp, Val, Ser or does not have3 Xaa is Ser, Gln, Pro, Leu, Val, Ala, Trp, Tyr or Phe,4 Xaa is Val or Ile,5 Xaa is Asp, Asn or Ile,6 Xaa is Pro, His or Ala,7 Xaa is Arg, Asn, Ser, Lys, Glu or Asp12 Xaa is Leu, Ile or Nle15 Xaa is Gly or Pro16 Xaa is Ser, Asn or Ala,17 Xaa is Gln, Lys or Thr18 Xaa is Pro or His,19 Xaa is Lys, Thr, Ser, Ala, Arg, Pro, Glu, Leu, Ile or Nle20 Xaa is Thr, Ala or Ile21 Xaa is Ala, Pro, Asp or Val22 Xaa is Cys or Ser23 Xaa is Thr, Asn or Ser24 Xaa is Asn, Lys, Arg, Gln, Ala, Pro or ThrPeptide comprises at least 6 continuous amino acids of the sequence of SEQ ID NO;

    1,Xaa 1?Xaa 2?Xaa 3?Phe?Xaa 5?Xaa 6?Xaa 7?Xaa 8?Xaa 9?Xaa 10?Xaa 11?Xaa 12-Z-Tyr?Xaa i?Gly?Xaa 15?Lys?Lys?Arg?Xaa 19?Xaa 20?Xaa 21?Xaa 22?Xaa 23(SEQ?ID?NO:

    4) Amino acid in its medium chain has following implication;

    1 Xaa is Pro, Ile, Leu, Thr, Tyr or Val2 Xaa is Val, Ala, Cys, Leu3 Xaa is Cys, Ile, Leu, Val or Nle5 Xaa is Ile, Leu, Gln, Met or Thr6 Xaa is Thr, Asn, Lys or Arg7 Xaa is Lys, Arg or Gln8 Xaa is Gly or Ala9 Xaa is Leu or Ile10 Xaa is Gly, Ser or Ala11 Xaa is Ile or Gly12 Xaa is Ser, Phe or TyrThe Xaa that before 14, inserts iBe Leu, Ile, Nle 15 Xaa is Arg, Lys, Ser or citrulline (Cit)19 Xaa is Arg, Lys, Ser, Gly or Cit20 Xaa is Gln, Arg or Pro21 Xaa is Ile or Leu22 Xaa is Gly, Leu, Ile, Cys or does not have23 Xaa is Gly or does not haveWherein the sequence of SEQ ID NO;

    4 comprises at least 6 successive amino acid, and-Z-is the implication of selectable linker and the PEG with PEG, modification and/or [Gly] n, n=1,2 or 3 wherein,Xaa 1?Ile?Leu?Xaa 4?Xaa 5?Xaa 6?Leu?Gly?Arg?Xaa 10?Xaa 11-Z-Xaa 12?Leu 13?Xaa i?Xaa i?Xaa 14?Xaa 15?Xaa 16?Xaa 17?Xaa 18?Xaa 19?Leu?Pro?Pro?Leu(SEQ?IDNO:

    7) Wherein 1 Xaa is Phe, Tyr, Trp or Arg4 Xaa is Gly, Ser, Asn, Asp, Cys, Val, Thr, Ala or Arg5 Xaa is Thr, Ala, Asp, Asn or Ser6 Xaa is Tyr, Cys, Phe, Arg, His, Ser, Val or Leu10 Xaa is Ser, Pro, Phe, Leu or Ile11 Xaa is Ala, Thr, Glu, Gln, Val, Pro or Ser12 Xaa is Glu, Lys, Gln, Asp, Asn, Tyr, Trp or PheThe Xaa that after 13, inserts iBe Ser, Pro, Phe, Leu or Ile The Xaa that before 14, inserts iBe Ala, Thr, Glu, Gln, Val, Pro or Ser 14 Xaa is Glu, Lys, Gln, Asp or Asn15 Xaa is Pro, Ser, Ala or Asn16 Xaa is Val, Asn, Gly or Pro17 Xaa is Pro, Gln, His, Ser, Leu, Arg, Thr, Asp or Ile18 Xaa is Leu, Phe or Val19 Xaa is Gln, Leu, Pro, His, Asp or GluWherein the sequence of SEQ ID NO;

    7 is made up of at least 6 successive amino acid, and linker-Z-is selectable and has the implication of PEG and/or [Gly] n of PEG, modification, n=1,2 or 3 wherein,Xaa 1?Leu?Val?Gly?Xaa5?Pro?Xaa 7?Xaa 8?Pro?Xaa 10?Xaa 11?Pro-Z-[Arg] mXaa i?Xaa 13?Xaa 14?Pro?Xaa 16?Xaa 17?Xaa 18?Xaa 19?Xaa 20?Xaa 21(SEQ?ID?NO:

    10) Wherein 1 Xaa is Lys or Arg5 Xaa is Phe or Leu7 Xaa is Ile or Val8 Xaa is Thr, Arg, Lys, Ala or Met10 Xaa is Gln or His11 Xaa is Val, Leu or IleThe Xaa that before 13, inserts iBe Leu 14 Xaa is Leu, Val or Thr15 Xaa is Arg or citrulline (Cit)17 Xaa is Met, Val, Ile or Nle, Leu18 Xaa is Thr or Asp19 Xaa is Tyr, Phe or Arg20 Xaa is Lys or Arg21 Xaa is Ala, Gly, Ser, Glu or Gln22 Xaa is Ala, Ser or ValWherein the sequence of SEQ ID NO;

    10 is made up of at least 6 successive amino acid, and linker-Z-is selectable and has the implication of PEG and/or [Gly] n of PEG, modification, n=1,2 or 3 wherein, and be independent of n, [Arg] mIn m be 0,1,2 or 3, The end of sequence can be free carboxyl group or amino group, acid amides, acyl group, ethanoyl or their salt,Two or more Cys residues can form in the chain or the part of interchain disulfide bond, promptly p=1-8 wherein-S-(CH 2) p-S-or-(CH 2) p-bridge selectively have one or more heteroatomss such as O, N and S to get involved, and/or said peptide sequence is fixed on the solid support.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×